Entero Therapeutics Secures $3M Through Pre-Funded And Common Warrants

Entero Therapeutics, Inc. (NASDAQ:ENTO) (the "Company"), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that it has entered into definitive agreements with institutional investors for the purchase and sale of approximately $3 million of pre-funded and common warrants. The entire transaction has been priced at the market under Nasdaq rules.

The offering consists of the sale of 4,878,841 pre-funded warrants and 9,757,682 common warrants to purchase one share of common stock per warrant. The combined purchase price for one pre-funded warrant and two common warrants is $0.6149.The pre-funded warrants will be immediately exercisable at an exercise price of $0.00001 and may be exercised at any time until exercised in full. The initial exercise price of each common warrant is $0.3649 per share of common stock and the common warrants are exercisable immediately and expire 60 months after the effective date of the resale registration statement registering the shares underlying the pre-funded warrants and common warrants or the date that such shares can be resold without restriction or limitation pursuant to Rule 144.

Aggregate gross proceeds to the Company are expected to be approximately $3.0 million. Approximately $1.0 million of the proceeds will be paid to the Company at closing and $2.0 million will be paid when the resale registration statement is declared effective. The transaction is expected to close on or about August 11, 2025, subject to the satisfaction of customary closing conditions. The Company expects to use the net proceeds from the offering, together with its existing cash, for general corporate purposes and working capital.